Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough

Phathom Pharmaceuticals came into this earnings print with a bruised stock chart, down double digits over the past month and quarter, and it slipped another 3.1% to US$8.75 in the first full trading day after results. The headline, however, is not the share price. The company reported its first quarter of operating profit on a cash basis excluding stock based compensation, on revenue of US$74.3m.

For a gastrointestinal focused biotech that has been firmly in loss making territory, that shift toward operating profitability and US$1.6m of positive operating cash flow is what really challenges the recent slide in Phathom Pharmaceuticals shares.

Is Phathom Pharmaceuticals a rare bargain at 2.9x P/S with a large gap to that US$189.23 per share DCF value, or is the balance sheet risk doing the real talking? Compare the current share price against the detailed valuation analysis for Phathom Pharmaceuticals.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$74.3m vs. US$39.5m (year-on-year increase of about 88%).
• Net Income / Loss, Q2 2026 vs. Q2 2025: loss of US$17.6m vs. loss of US$75.8m (loss narrowed materially).
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.21 per share vs. loss of US$1.05 per share (per share loss narrowed sharply).
• Operating Cash Flow, Q2 2026 vs. Q2 2025: positive US$1.6m vs. a loss position a year ago (moved into positive operating cash flow on a cash basis excluding stock-based compensation).

Prefer clean visuals instead of paging through earnings tables and cash flow statements for Phathom Pharmaceuticals? View a full picture of how the market is valuing the business right now with an easy-to-scan valuation breakdown in the company report for Phathom Pharmaceuticals.

Phathom Pharmaceuticals bull story meets real cash tests

Bulls argue that Phathom Pharmaceuticals is on a clear path to sustainable profitability driven by VOQUEZNA growth, operating leverage, and disciplined spend. Q2 goes a long way toward backing that up. Revenue reached US$74.3m with about 325,000 prescriptions in the quarter and roughly 1.7m since launch, which supports the claim of growing adoption among gastroenterologists. Cash operating expenses excluding stock based compensation fell 34% year on year and the company delivered its first operating profit on that basis, plus about US$1.6m of positive operating cash flow. Management also reiterated 2026 revenue guidance of US$310m to US$325m and cash OpEx of US$235m to US$245m, and reaffirmed the target for durable cash flow positivity in 2027. With US$182.5m of cash and no stated need for new capital, key milestones on cost control and self funding operations are being hit.

Bear case focuses on concentration and execution risk

The bear story centers on heavy dependence on VOQUEZNA, pricing and reimbursement friction, and the risk that profitability slips or requires new capital. Q2 data shows that concentration risk remains intact. Revenue is still tied to a narrow set of GI assets and management itself pointed to payer and office workflow friction as the main brake on broader use, which is why the 2026 revenue range was refined. Covered prescriptions grew faster than cash scripts, but a 55% to 59% gross to net range signals ongoing discounting and payer pressure. Although cash OpEx is falling and operating profit excluding stock based compensation turned positive, GAAP net loss was still US$17.6m. The stock has fallen about 27% over 90 days, which suggests investors continue to price in the risk that label expansion, primary care uptake and pipeline diversification may take longer or cost more than bulls hope.

Compare how Phathom Pharmaceuticals is talking about VOQUEZNA driven progress with what the Street is expecting. See the consensus price target analysis for Phathom Pharmaceuticals to check whether analysts think this story lines up with their targets.

Take Control of Your Next Move

If the shift in Phathom Pharmaceuticals cash profitability and the gap to that DCF value has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the thesis develops. After you decide to build a position, use the Portfolio Command Center to keep your holdings organised and surface only the key alerts that matter for your risk and return goals. For a longer term view, tap into crowd insights and debate around Phathom Pharmaceuticals and similar stocks through the Community to see how other investors are interpreting the same data. This way you can spot potential catalysts and risks early and stay a step ahead of the market.

Seeking Alternatives Beyond Phathom Pharmaceuticals

Fresh ideas are moving toward potential breakout and momentum can be caught or missed fast. Scan these under the radar for now opportunities before the crowd and get in early.

• Spot income workhorses that could help keep a portfolio grounded while markets swing by reviewing the curated 9 dividend fortresses and seeing which yields still look compelling before they potentially get bid up.
• Chase quality growth where balance sheets do the heavy lifting by scanning the hand picked list of solid balance sheet and fundamentals stocks (45 results) while these businesses are still priced as if momentum has not arrived.
• Hunt for potential breakout leaders related to AI infrastructure by checking the focused 57 AI infrastructure stocks before capital flows potentially crowd into the same infrastructure stories and valuations start moving.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com